ADMA Biologics, Inc.

NASDAQ:ADMA

Biotechnology

Healthcare
$13.56 +0.42%

+$0.04 today

Market cap
$3.01B
Beta
0.73
P/E (TTM)
12.1
EPS (TTM)
$0.70
52W Low $7.21High $20.46

Volume 3.17M

Average 7.07M

ADMA Operating Expenses

Total costs of running the business that are not directly tied to producing goods or services sold.

ADMA Biologics, Inc.NASDAQ: ADMA

Operating Expenses · Q2 FY2026 · quarter ended Jun 2026

Operating expenses growth accelerates

Q2 FY2026 operating expenses of $33.83M rose 38.5% year over year, ahead of the +20.1% change in trailing-twelve-month operating expenses. Sequentially, it rose 11.3% from the prior quarter. Over 3 fiscal years it compounded at +10.7% a year.

Context

  • Operating expenses amounted to 19.9% of revenue in FY2025, up 1.0 pp from a year earlier.
  • Operating expenses increased in 2 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth of +38.5% holds above the trailing-twelve-month pace of +20.1%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterJun 2026
$33.83M+11.3% QoQ
Last fiscal yearDec 2025
$101.32M+25.8% YoY
LTMJun 2026
$114.91M+20.1% YoY
Operating Expenses past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+38.5%——
1 year+25.8%——
3-year CAGR+10.7%——
5-year CAGR——
10-year CAGR——

Operating Expenses history

USD · from the income statement

Latest · FY2025
101.32M USD
Year-over-year change
+25.8%
4-year CAGR
+14.2%

Operating Expenses vs competitors

How ADMA compares with its peers on the latest reported figures

  • Peers report in different currencies, so operating expenses is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +20.1% is the highest of 4, against a peer median of -26.8%.
  • Operating expenses amounts to 22.4% of revenue for ADMA, versus a peer median of 20.6%.
ADMA Competitors
Operating Expenses for ADMA and competitors
Company Period LTM YoY 3-year CAGR% of revenue
GRFSGrifols, S.A.LTM Jun 2026€1.53B EUR-6.5%-0.9%20.6%
IVVDInvivyd, Inc.LTM Mar 2026$133.18M USD-26.8%-24.9%238.4%
ADMAADMA Biologics, Inc.LTM Jun 2026$114.91M USD+20.1%+10.7%22.4%
ABUSArbutus Biopharma CorporationLTM Mar 2026$36.74M USD-54.2%-26.9%19.2%
Peer median (excluding ADMA) —-26.8%-24.9%20.6%

Competitors are the stored peer set for ADMA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue80.94M154.08M258.22M426.45M510.17M
Cost of Revenue79.77M118.82M169.27M206.9M217.41M
Gross Profit1.17M35.27M88.94M219.55M292.77M
Gross Margin1.4%22.9%34.4%51.5%57.4%
Research & Development3.65M3.61M3.3M1.81M4.76M
Selling, General & Admin42.9M52.46M59.02M74.12M91.58M
Operating Expenses59.55M74.63M67.31M80.57M101.32M
Depreciation & Amortization5.5M7.11M8.33M8.05M8.1M
EBITDA(53.1M)(39.51M)5.12M147.69M197.86M
EBITDA Margin-65.6%-25.6%2.0%34.6%38.8%
Operating Income(58.37M)(39.37M)21.63M138.98M191.44M
Operating Margin-72.1%-25.5%8.4%32.6%37.5%
Interest Income34.53K44.83K1.62M2.1M1.87M
Interest Expense13.06M19.28M25.03M13.93M7.11M
Other Income / Expenses(13.27M)(26.54M)(49.87M)(13.27M)(8.79M)
Income Before Tax(71.65M)(65.9M)(28.24M)125.71M182.66M
Pre-Tax Margin-88.5%-42.8%-10.9%29.5%35.8%
Income Tax Expense000(71.96M)35.73M
Net Income(71.65M)(65.9M)(28.24M)197.67M146.93M
Net Margin-88.5%-42.8%-10.9%46.4%28.8%
EPS (Basic)(0.61)(0.43)(0.13)0.850.62
EPS (Diluted)(0.61)(0.43)(0.13)0.810.60
Weighted Avg Shares139.58M197.87M223.98M233.08M238.3M
Weighted Avg Shares (Diluted)139.58M197.87M223.98M243.34M244.9M

ADMA Biologics, Inc.

NASDAQ:ADMA

Intrinsic Alpha fair value

Locked

Current Price

$13.56

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.